Table 1.

Development and evaluation of the community-based buprenorphine treatment (CBBT) intervention components

Method	Content description	Evaluation
Component 1: Buprenorphine Educationa
Slide presentation	8 modules: introduction; background information on buprenorphine; what is buprenorphine; who can take buprenorphine; getting on buprenorphine; buprenorphine and the brain; buprenorphine/naloxone vs. buprenorphine alone; effectiveness and safety of buprenorphine; being involved in your buprenorphine treatment	Mean satisfactionb = 1.9 Pre-post knowledge increased from 50 to 79% of answers correct.c
Frequently asked questions	30 questions frequently asked by people seeking buprenorphine treatment
Resource guide	Resources (websites and phone numbers) that provide buprenorphine information and list buprenorphine-prescribing physicians
Glossary of terms	42 frequently used terms associated with opioid addiction and buprenorphine
Myths and facts about buprenorphine	16 commonly held myths regarding buprenorphine, and the facts regarding these statements
Component 2: Motivational Interviewingd
Slide presentation	Components: what is motivational interviewing; stages of change; key principles of motivational interviewing	Mean satisfactione = 4.5
Workbook	Self-reflection activities, stages of change clinical scenarios, role-playing activities
Component 3: Facilitate access to buprenorphine-prescribing physicians
Identification of buprenorphine-prescribing physicians	Interactive exercises using websites to locate buprenorphine-prescribing physicians	Mean satisfactionb = 1.6
Facilitate clients’ accessing buprenorphine treatment	Role play phone calls to doctors’ offices inquiring about buprenorphine treatment; exploration of process to initiate buprenorphine treatment; role play potential structural barriers (insurance issues, medication cost, transportation)
Component 4: Support during buprenorphine treatment
Case scenarios with common treatment challenges	Group discussion of 4 case scenarios that represent common treatment challenges: use of illicit buprenorphine; relapse; polysubstance use; severe untreated mental illness.	Mean satisfactionb = 1.6

^aModified from the New York City Department of Health and Mental Hygiene’s Buprenorphine Educational Curriculum

^bSatisfaction was measured using an 8-item questionnaire that rated importance, usefulness, comfort, and appropriateness of the trainings’ content and structure. Ratings used a Likert scale from 1 to 4, where 1 = highly satisfied and 4 = highly dissatisfied

^cKnowledge was measured before and after the training via a 5-item multiple choice questionnaire

^dDeveloped and delivered by the Harm Reduction Coalition [44]

^eSatisfaction was measured using a Likert scale from 1 to 5, where 1 = poor and 5 = excellent